Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-05-2016 | Retinal Disorders

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

Authors: Tom Kornhauser, Roy Schwartz, Michaella Goldstein, Meira Neudorfer, Anat Loewenstein, Adiel Barak

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 5/2016

Abstract

Purpose

To assess the efficacy and safety of intraocular injections of bevacizumab in patients with macular edema (ME) following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

Methods

Retrospective, non-comparative case series. Patients ≥18 years of age with ME secondary to BRVO or CRVO who received a minimum of one intravitreal injection of bevacizumab with a follow-up >3 months were included. Primary endpoints were mean change in best corrected visual acuity (BCVA) from baseline to 12 and 24 months, and mean change in central macular thickness (CMT) after 3 injections. Secondary endpoints were mean change in BCVA and CMT from baseline to end of follow-up, number of injections, and ocular adverse events.

Results

Eighty-seven eyes with BRVO and 65 eyes with CRVO were included. Mean follow-up time was 24.4 and 26.1 months in the BRVO and CRVO groups, respectively. The mean change in BCVA was 0.25 LogMAR in the BRVO group and −0.118 LogMAR in the CRVO group.

Conclusion

Visual acuity outcomes in the CRVO group were poorer, especially in patients with low baseline BCVA.

Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732. doi:10.1001/archopht.124.5.726 CrossRefPubMed

The Royal College of Ophthalmologists, Interim Guidelines for Management of Retinal Vein Occlusion, December 2010. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010-SCI-095-RVO-Interim-Guidelines-Dec-2010-FINAL.pdf. Accessed 6 May 2015

Lucentis 10 mg/ml solution for injection - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/medicine/19409. Accessed 6 May 2015

Eylea 40mg/ml solution for injection in a vial - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/medicine/27224. Accessed 6 May 2015

Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 117:1102–1112.e1. doi:10.1016/j.ophtha.2010.02.021 CrossRefPubMed

Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for Macular Edema following Central Retinal Vein Occlusion. Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. doi:10.1016/j.ophtha.2010.02.022

Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809. doi:10.1016/j.ophtha.2011.12.005 CrossRefPubMed

Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339PubMed

PAT survey highlights shifting trends in practice preferences | OSN Retina. http://www.healio.com/ophthalmology/retina-vitreous/news/print/osn-retina/%7B857f9212-d7f4-4cff-b9f3-6d0f85748c8a%7D/pat-survey-highlights-shifting-trends-in-practice-preferences. Accessed 6 May 2015

10.

Epstein DL, Algvere PV, Von Wendt G et al (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591. doi:10.1016/j.ophtha.2012.06.037 CrossRefPubMed

11.

Prager F, Michels S, Kriechbaum K et al (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. doi:10.1136/bjo.2008.141085

12.

Zhang H, Liu Z-L, Sun P, Gu F (2011) Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 27:615–621. doi:10.1089/jop.2011.0050 CrossRefPubMed

13.

Braithwaite T, Nanji AA, Greenberg PB (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev CD007325. doi:10.1002/14651858.CD007325.pub2

14.

Pielen A, Feltgen N, Isserstedt C et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8:e78538. doi:10.1371/journal.pone.0078538 CrossRefPubMedPubMedCentral

15.

Brown DM, Wykoff CC, Wong TP, et al. (9000) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: The Rubeosis Anti-VEGF (RAVE) Trial. Retina. doi:10.1097/IAE.0000000000000191

16.

Campochiaro PA, Brown DM, Awh CC et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049. doi:10.1016/j.ophtha.2011.02.038 CrossRefPubMed

17.

Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594–1602. doi:10.1016/j.ophtha.2011.02.022 CrossRefPubMed

18.

Central T, Occlusion V, Group S, Library PM (1997) Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486–91

19.

Hayreh SS (2014) Ocular vascular occlusive disorders: Natural history of visual outcome. Prog Retin Eye Res 41C:1–25. doi:10.1016/j.preteyeres.2014.04.001 CrossRef

20.

Hayreh SS, Rojas P, Podhajsky P et al (1983) Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 90:488–506CrossRefPubMed

Title: Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)
Authors: Tom Kornhauser
Roy Schwartz
Michaella Goldstein
Meira Neudorfer
Anat Loewenstein
Adiel Barak
Publication date: 01-05-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 5/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-015-3130-z

At a glance: The STEP trials

Springer Medicine

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2016

Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy

Visual outcomes after femtosecond-assisted intracorneal MyoRing implantation: 18 months of follow-up

Erratum to: Effect of different culture media and deswelling agents on survival of human corneal endothelial and epithelial cells in vitro

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up)

Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease

Phacoaspiration with a Cionni ring versus pars plana lensectomy, vitrectomy and sutureless transscleral IOL fixation in pediatric patients with a subluxated lens